Urinary Tract Infection (UTI) Market Size by Drug Class (Quinolones, Aminoglycosides, ?-Lactam, Azoles), Pathogen Type (E. coli, Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecalis), Clinical Indication (Uncomplicated UTI, Complicated UTI, Recurring UTI), End-User (Hospitals, Gynecology and Urology Clinics, Academic and Research Institutions), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) & Region for 2024-2031

Report ID: 31458|No. of Pages: 202

product image

Urinary Tract Infection (UTI) Market Size by Drug Class (Quinolones, Aminoglycosides, ?-Lactam, Azoles), Pathogen Type (E. coli, Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecalis), Clinical Indication (Uncomplicated UTI, Complicated UTI, Recurring UTI), End-User (Hospitals, Gynecology and Urology Clinics, Academic and Research Institutions), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) & Region for 2024-2031

Report ID: 31458|Published Date: Nov 2024|No. of Pages: 202|Base Year for Estimate: CAGR of ~3.9% from 2024 to 2031|Format:   Report available in PDF formatReport available in Excel Format

Urinary Tract Infection (UTI) Market- 2024-2031

The Urinary Tract Infection (UTI) Market is expanding due to the increasing prevalence of UTIs across all age groups and genders. Technological advancements in diagnostic tools and the development of novel antibiotics are driving demand, with healthcare providers increasingly adopting these solutions for effective UTI management. This is likely to enable the market size to surpass USD 591.8 Million valued in 2024 to reach a valuation of around USD 803.72 Million by 2031.

Additionally, the market is seeing growth from the rising awareness about UTI prevention and treatment, which is driving the need for advanced therapeutic options. Moreover, increasing healthcare expenditure and improving access to medical care in developing countries are contributing to the market’s expansion. The rising demand for UTI treatments is enabling the market to grow at a CAGR of 3.9% from 2024 to 2031.

Urinary Tract Infection (UTI) Market is estimated to grow at a CAGR of 3.9% & reach US$ 803.72 Mn by the end of 2031

 

Urinary Tract Infection (UTI) Market Definition/Overview

Urinary Tract Infections (UTIs) are bacterial infections that can affect any part of the urinary system, including the kidneys, ureters, bladder and urethra. They are among the most common bacterial infections, particularly affecting women, the elderly and individuals with compromised immune systems.

Treatment typically involves antibiotics, with the choice depending on the specific pathogen and the severity of the infection. The market encompasses various aspects of UTI management, including diagnostics, therapeutics and preventive measures.

Future scope includes increasing advancements in rapid diagnostic techniques, development of novel antibiotics to combat antibiotic-resistant strains and growing focus on non-antibiotic alternatives for prevention and treatment. The persistent high incidence of UTIs and the need for effective management strategies are contributing to the expanding market potential for UTI-related products and services.

What's inside a VMR
industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

vmr

>>> Ask For Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=31458

How Is the Increasing Prevalence of UTIs Across All Age Groups Driving the Growth of The Urinary Tract Infection (UTI) Market?

The increasing prevalence of urinary tract infections (UTIs) in all age groups is considerably driving the UTI market. Aging populations, growing drug resistance, and lifestyle changes all contribute to an increase in UTI incidence. As more people look for effective treatment alternatives, there is a greater need for improved diagnostic technologies, medicines, and preventive measures.

Rising awareness of UTIs and associated complications encourages healthcare professionals to prioritize prevention and early intervention, accelerating market growth. The proliferation of telehealth services improves access to healthcare, allowing more people to seek prompt treatment. As a result, pharmaceutical companies and medical device manufacturers are investing in research and development to accommodate the growing demand, resulting to breakthroughs in UTI management and an an expanding market landscape.

How Does the Growing Concern of Antibiotic Resistance Challenge the Growth of The Urinary Tract Infection (UTI) Market?

The growing concern of antibiotic resistance poses a significant challenge to market growth by limiting the effectiveness of traditional UTI treatments. The overuse and misuse of antibiotics have led to the emergence of resistant bacterial strains, making some infections harder to treat. Consequently, healthcare providers may need to use more expensive or less convenient treatment options, potentially reducing patient compliance and treatment success rates. This challenge can hinder the development and adoption of new antibiotic therapies, ultimately impacting the overall expansion and potential of the UTI market.

Category-wise Acumens

How Will the Increasing Effectiveness of Quinolones in Treating Complicated UTIs Drive the Growth of The Quinolones Segment?

The quinolones segment is predicted to develop because to their increased effectiveness in treating severe urinary tract infections (UTIs). Factors such as the increasing prevalence of multidrug-resistant UTI bacteria and quinolones’ great efficiency against these strains have been identified. Quinolone-based medicines are also becoming more popular due to better bioavailability and patient compliance as a result of simple dosing schedules.

Furthermore, clinical recommendations supporting quinolones as a first-line treatment for complex UTIs have been developed. As healthcare professionals increasingly follow these suggestions, demand for quinolone antibiotics is expected to rise, accelerating the segment’s growth. Research and development efforts aimed at enhancing quinolone formulations are expected to improve treatment outcomes and patient satisfaction.

How Will the Growing Prevalence of E. Coli-Induced UTIs Drive the Growth of The E. coli Pathogen Segment?

The growing prevalence of E. coli-induced UTIs will drive the growth of the E. coli pathogen segment in the UTI Market. E. coli remains the most common causative agent for UTIs, responsible for a significant proportion of both community-acquired and hospital-acquired infections. This prevalence appeals to both researchers and pharmaceutical companies, enhancing the development of targeted therapies. As the demand for effective treatments against E. coli-induced UTIs increases, the E. coli pathogen segment is positioned for significant growth.

Gain access into Urinary Tract Infection (UTI) Market Methodology

https://www.verifiedmarketresearch.com/select-licence/?rid=31458

Country/Region-wise Acumens

Will The Advanced Healthcare Infrastructure and High Healthcare Expenditure Drive the Dominance of North America in The Urinary Tract Infection (UTI) Market?

The advanced healthcare infrastructure and high healthcare expenditure will drive the dominance of North America in the UTI Market. With significant investment in healthcare research and development, the demand for innovative UTI diagnostics and treatments is increasing. Moreover, the region’s robust healthcare system supports rapid adoption of new therapeutic options, allowing for better patient outcomes. The presence of leading pharmaceutical companies and strong research initiatives further enhances North America’s position as a key player in this market.

Will Increasing Awareness About UTI Prevention Drive the Rapid Growth Of The Asia-Pacific Region In The Urinary Tract Infection (UTI) Market?

Increasing awareness about UTI prevention and improving healthcare access will drive the rapid growth of the Asia-Pacific region in the UTI market. As more individuals in the region become aware of UTI symptoms and seek timely medical attention, demand for UTI treatments is expected to rise. Improved healthcare infrastructure facilitates access to advanced diagnostic and therapeutic options, making them more widely available. Additionally, the large population base in this region further contributes to the increasing need for UTI management solutions, supporting market expansion.

Competitive Landscape

The Urinary Tract Infection (UTI) market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions and political support. The organizations are focusing on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the Urinary Tract Infection (UTI) market include:

  • Pfizer Inc.
  • Johnson & Johnson Services, Inc.
  • GlaxoSmithKline plc
  • Novartis AG
  • Hoffmann-La Roche Ltd
  • AstraZeneca
  • Bayer AG
  • Merck & Co., Inc.
  • Abbott Laboratories
  • Cipla Ltd.

Latest Developments

Urinary Tract Infection (UTI) Market Key Developments

  • In March 2023, GSK plc announced positive results from a Phase III trial for gepotidacin, a novel antibiotic for the treatment of uncomplicated urinary tract infections (uUTI), potentially offering a new treatment option for antibiotic-resistant infections.
  • In January 2023, Iterum Therapeutics plc reported positive topline results from its REASSURE clinical trial of oral sulopenem for the treatment of uncomplicated urinary tract infections.
  • In November 2022, Allecra Therapeutics announced that the U.S. FDA has accepted for review its New Drug Application (NDA) for cefepime/enmetazobactam for the treatment of complicated urinary tract infections (cUTIs).
  • In October 2022, Venatorx Pharmaceuticals announced positive results from its pivotal Phase 3 study of cefepime-taniborbactam, a new antibiotic for the treatment of complicated urinary tract infections (cUTIs).

Report Scope

REPORT ATTRIBUTESDETAILS
Study Period

2021-2031

Growth Rate

CAGR of ~3.9% from 2024 to 2031

Base Year for Valuation

2024

Historical Period

2024-2031

Forecast Period

2021-2023

Quantitative Units

Value in USD Million

Report Coverage

Historical and Forecast Revenue Forecast, Historical and Forecast Volume, Growth Factors, Trends, Competitive Landscape, Key Players, Segmentation Analysis

Segments Covered
  • By Drug Class
  • By Pathogen Type
  • By Clinical Indication
  • By End-User
  • By Distribution Channel
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Key Players

Lockheed Pfizer Inc., Johnson & Johnson Services, Inc., GlaxoSmithKline plc, Novartis AG, F. Hoffmann-La Roche Ltd, AstraZeneca, Bayer AG, Merck & Co., Inc., Abbott Laboratories, Cipla Ltd.

 

Customization

Report customization along with purchase available upon request

Urinary Tract Infection (UTI) Market, by Category

Drug Class:

  • Quinolones
  • Aminoglycosides
  • ?-Lactam
  • Azoles

Pathogen Type:

  • coli
  • Klebsiella pneumoniae
  • Proteus mirabilis
  • Enterococcus faecalis

Clinical Indication:

  • Uncomplicated UTI
  • Complicated UTI
  • Recurring UTI

End-User:

  • Hospitals
  • Gynecology and Urology Clinics
  • Academic and Research Institutions

Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Region:

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Research Methodology of Verified Market Research:

Research Methodology of VMR

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our Sales Team at Verified Market Research.

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
• Provision of market value (USD Billion) data for each segment and sub-segment
• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
• The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
• Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
• Provides insight into the market through Value Chain
• Market dynamics scenario, along with growth opportunities of the market in the years to come
• 6-month post-sales analyst support

Customization of the Report

• In case of any Queries or Customization Requirements please connect with our sales team, who will ensure that your requirements are met.

Frequently Asked Questions

Some of the key players leading in the urinary tract infection (UTI) market include Lockheed Pfizer Inc., Johnson & Johnson Services, Inc., GlaxoSmithKline plc, Novartis AG, F. Hoffmann-La Roche Ltd, AstraZeneca, Bayer AG, Merck & Co., Inc., Abbott Laboratories, Cipla Ltd.

The primary factor driving the urinary tract infection (UTI) market is the increasing prevalence of UTIs globally, coupled with growing awareness and demand for effective treatment options.

The urinary tract infection (UTI) market is estimated to grow at a CAGR of 3.9% during the forecast period.

The urinary tract infection (UTI) market was valued at around USD 591.8 Million in 2024.

The sample report for the Urinary Tract Infection Market can be obtained on demand from the website. Also, 24*7 chat support & direct call services are provided to procure the sample report.

1 INTRODUCTION OF THE GLOBAL URINARY TRACT INFECTION MARKET
1.1 Market Definition
1.2 Market Segmentation
1.3 Research Timelines
1.4 Assumptions
1.5 Limitations

2 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH
2.1 Data Mining
2.2 Data Triangulation
2.3 Bottom-Up Approach
2.4 Top-Down Approach
2.5 Research Flow
2.6 Key Insights from Industry Experts
2.7 Data Sources

3 EXECUTIVE SUMMARY
3.1 Market Overview
3.2 Ecology Mapping
3.3 Absolute Market Opportunity
3.4 Market Attractiveness
3.5 Global Urinary Tract Infection Market Geographical Analysis (CAGR %)
3.6 Global Urinary Tract Infection Market, By Type (USD Million)
3.7 Global Urinary Tract Infection Market, By End-Users (USD Million)
3.8 Future Market Opportunities
3.9 Global Market Split
3.10 Product Life Line

4 GLOBAL URINARY TRACT INFECTION MARKET OUTLOOK
4.1 Global Urinary Tract Infection Evolution
4.2 Drivers
4.2.1 Driver 1
4.2.2 Driver 2
4.3 Restraints
4.3.1 Restraint 1
4.3.2 Restraint 2
4.4 Opportunities
4.4.1 Opportunity 1
4.4.2 Opportunity 2
4.5 Porters Five Force Model
4.6 Value Chain Analysis
4.7 Pricing Analysis
4.8 Macroeconomic Analysis

5 GLOBAL URINARY TRACT INFECTION MARKET, BY TYPE
5.1 Overview
5.2 Cystitis
5.3 Urethritis
5.4 Pyelonephritis

6 GLOBAL URINARY TRACT INFECTION MARKET, BY END-USERS
6.1 Overview
6.2 General practitioners (GPs)
6.3 Urogynecologists
6.4 Hospital Laboratories
6.5 Others

7 GLOBAL URINARY TRACT INFECTION MARKET, BY GEOGRAPHY
7.1 Overview
7.2 North America
7.2.1 U.S.
7.2.2 Canada
7.2.3 Mexico
7.3 Europe
7.3.1 Germany
7.3.2 U.K.
7.3.3 France
7.3.4 Italy
7.3.5 Spain
7.3.6 Rest of Europe
7.4 Asia Pacific
7.4.1 China
7.4.2 Japan
7.4.3 India
7.4.4 Rest of Asia Pacific
7.5 Latin America
7.5.1 Brazil
7.5.2 Argentina
7.5.3 Rest of Latin America
7.6 Middle East and Africa
7.6.1 UAE
7.6.2 Saudi Arabia
7.6.3 South Africa
7.6.4 Rest of Middle-East and Africa

8 GLOBAL URINARY TRACT INFECTION MARKET COMPETITIVE LANDSCAPE
8.1 Overview
8.2 Company Market Ranking
8.3 Key Developments
8.4 Company Regional Footprint
8.5 Company Industry Footprint
8.6 ACE Matrix

9 COMPANY PROFILES

9.1 Bayer AG
9.1.1 Company Overview
9.1.2 Company Insights
9.1.3 Product Benchmarking
9.1.4 Key Developments
9.1.5 Winning Imperatives
9.1.6 Current Focus & Strategies
9.1.7 Threat from Competition
9.1.8 SWOT Analysis

9.2 Cipla
9.2.1 Company Overview
9.2.2 Company Insights
9.2.3 Product Benchmarking
9.2.4 Key Developments
9.2.5 Winning Imperatives
9.2.6 Current Focus & Strategies
9.2.7 Threat from Competition
9.2.8 SWOT Analysis

9.3 Pfizer
9.3.1 Company Overview
9.3.2 Company Insights
9.3.3 Product Benchmarking
9.3.4 Key Developments
9.3.5 Winning Imperatives
9.3.6 Current Focus & Strategies
9.3.7 Threat from Competition
9.3.8 SWOT Analysis

9.4 GlaxoSmithKline
9.4.1 Company Overview
9.4.2 Company Insights
9.4.3 Product Benchmarking
9.4.4 Key Developments
9.4.5 Winning Imperatives
9.4.6 Current Focus & Strategies
9.4.7 Threat from Competition
9.4.8 SWOT Analysis

9.5 Shionogi & Co., Ltd
9.5.1 Company Overview
9.5.2 Company Insights
9.5.3 Product Benchmarking
9.5.4 Key Developments
9.5.5 Winning Imperatives
9.5.6 Current Focus & Strategies
9.5.7 Threat from Competition
9.5.8 SWOT Analysis

9.6 AstraZeneca
9.6.1 Company Overview
9.6.2 Company Insights
9.6.3 Product Benchmarking
9.6.4 Key Developments
9.6.5 Winning Imperatives
9.6.6 Current Focus & Strategies
9.6.7 Threat from Competition
9.6.8 SWOT Analysis

9.7 Hoffmann-La Roche
9.7.1 Company Overview
9.7.2 Company Insights
9.7.3 Product Benchmarking
9.7.4 Key Developments
9.7.5 Winning Imperatives
9.7.6 Current Focus & Strategies
9.7.7 Threat from Competition
9.7.8 SWOT Analysis

9.8 Johnson & Johnson
9.8.1 Company Overview
9.8.2 Company Insights
9.8.3 Product Benchmarking
9.8.4 Key Developments
9.8.5 Winning Imperatives
9.8.6 Current Focus & Strategies
9.8.7 Threat from Competition
9.8.8 SWOT Analysis

9.9 Novartis AG
9.9.1 Company Overview
9.9.2 Company Insights
9.9.3 Product Benchmarking
9.9.4 Key Developments
9.9.5 Winning Imperatives
9.9.6 Current Focus & Strategies
9.9.7 Threat from Competition
9.9.8 SWOT Analysis

9.10 Reddy’s Laboratories Ltd.
9.10.1 Company Overview
9.10.2 Company Insights
9.10.3 Product Benchmarking
9.10.4 Key Developments
9.10.5 Winning Imperatives
9.10.6 Current Focus & Strategies
9.10.7 Threat from Competition
9.10.8 SWOT Analysis

10. VERIFIED MARKET INTELLIGENCE
10.1 About Verified Market Intelligence
10.2 Dynamic Data Visualization

Report Research Methodology

Research methodology

Verified Market Research uses the latest researching tools to offer accurate data insights. Our experts deliver the best research reports that have revenue generating recommendations. Analysts carry out extensive research using both top-down and bottom up methods. This helps in exploring the market from different dimensions.

This additionally supports the market researchers in segmenting different segments of the market for analysing them individually.

We appoint data triangulation strategies to explore different areas of the market. This way, we ensure that all our clients get reliable insights associated with the market. Different elements of research methodology appointed by our experts include:

Exploratory data mining

Market is filled with data. All the data is collected in raw format that undergoes a strict filtering system to ensure that only the required data is left behind. The leftover data is properly validated and its authenticity (of source) is checked before using it further. We also collect and mix the data from our previous market research reports.

All the previous reports are stored in our large in-house data repository. Also, the experts gather reliable information from the paid databases.

expert data mining

For understanding the entire market landscape, we need to get details about the past and ongoing trends also. To achieve this, we collect data from different members of the market (distributors and suppliers) along with government websites.

Last piece of the ‘market research’ puzzle is done by going through the data collected from questionnaires, journals and surveys. VMR analysts also give emphasis to different industry dynamics such as market drivers, restraints and monetary trends. As a result, the final set of collected data is a combination of different forms of raw statistics. All of this data is carved into usable information by putting it through authentication procedures and by using best in-class cross-validation techniques.

Data Collection Matrix

PerspectivePrimary ResearchSecondary Research
Supplier side
  • Fabricators
  • Technology purveyors and wholesalers
  • Competitor company’s business reports and newsletters
  • Government publications and websites
  • Independent investigations
  • Economic and demographic specifics
Demand side
  • End-user surveys
  • Consumer surveys
  • Mystery shopping
  • Case studies
  • Reference customer

Econometrics and data visualization model

data visualiztion model

Our analysts offer market evaluations and forecasts using the industry-first simulation models. They utilize the BI-enabled dashboard to deliver real-time market statistics. With the help of embedded analytics, the clients can get details associated with brand analysis. They can also use the online reporting software to understand the different key performance indicators.

All the research models are customized to the prerequisites shared by the global clients.

The collected data includes market dynamics, technology landscape, application development and pricing trends. All of this is fed to the research model which then churns out the relevant data for market study.

Our market research experts offer both short-term (econometric models) and long-term analysis (technology market model) of the market in the same report. This way, the clients can achieve all their goals along with jumping on the emerging opportunities. Technological advancements, new product launches and money flow of the market is compared in different cases to showcase their impacts over the forecasted period.

Analysts use correlation, regression and time series analysis to deliver reliable business insights. Our experienced team of professionals diffuse the technology landscape, regulatory frameworks, economic outlook and business principles to share the details of external factors on the market under investigation.

Different demographics are analyzed individually to give appropriate details about the market. After this, all the region-wise data is joined together to serve the clients with glo-cal perspective. We ensure that all the data is accurate and all the actionable recommendations can be achieved in record time. We work with our clients in every step of the work, from exploring the market to implementing business plans. We largely focus on the following parameters for forecasting about the market under lens:

  • Market drivers and restraints, along with their current and expected impact
  • Raw material scenario and supply v/s price trends
  • Regulatory scenario and expected developments
  • Current capacity and expected capacity additions up to 2027

We assign different weights to the above parameters. This way, we are empowered to quantify their impact on the market’s momentum. Further, it helps us in delivering the evidence related to market growth rates.

Primary validation

The last step of the report making revolves around forecasting of the market. Exhaustive interviews of the industry experts and decision makers of the esteemed organizations are taken to validate the findings of our experts.

The assumptions that are made to obtain the statistics and data elements are cross-checked by interviewing managers over F2F discussions as well as over phone calls.

primary validation

Different members of the market’s value chain such as suppliers, distributors, vendors and end consumers are also approached to deliver an unbiased market picture. All the interviews are conducted across the globe. There is no language barrier due to our experienced and multi-lingual team of professionals. Interviews have the capability to offer critical insights about the market. Current business scenarios and future market expectations escalate the quality of our five-star rated market research reports. Our highly trained team use the primary research with Key Industry Participants (KIPs) for validating the market forecasts:

  • Established market players
  • Raw data suppliers
  • Network participants such as distributors
  • End consumers

The aims of doing primary research are:

  • Verifying the collected data in terms of accuracy and reliability.
  • To understand the ongoing market trends and to foresee the future market growth patterns.

Industry Analysis Matrix

Qualitative analysisQuantitative analysis
  • Global industry landscape and trends
  • Market momentum and key issues
  • Technology landscape
  • Market’s emerging opportunities
  • Porter’s analysis and PESTEL analysis
  • Competitive landscape and component benchmarking
  • Policy and regulatory scenario
  • Market revenue estimates and forecast up to 2027
  • Market revenue estimates and forecasts up to 2027, by technology
  • Market revenue estimates and forecasts up to 2027, by application
  • Market revenue estimates and forecasts up to 2027, by type
  • Market revenue estimates and forecasts up to 2027, by component
  • Regional market revenue forecasts, by technology
  • Regional market revenue forecasts, by application
  • Regional market revenue forecasts, by type
  • Regional market revenue forecasts, by component

Urinary Tract Infection Market

report-detail

Download Sample Report

View More Reports